{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:43:13Z","timestamp":1793356993436,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Doctor of Pharmacy (PharmD) thesis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The Evoque\u2122 transcatheter tricuspid valve replacement (TTVR) system demonstrated superiority over optimal medical treatment (OMT) in the TRISCEND II trial. We aimed to evaluate the cost-effectiveness of TTVR in patients with severe Tricuspid Regurgitation (TR) from the French healthcare perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A state-transition Markov model was developed to assess the cost-effectiveness of Evoque\u2122 TTVR versus OMT alone over a lifetime horizon. The modelled cohort reflected the TRISCEND II population. Health states were defined by TR severity (none\/trace, mild, moderate, severe) and death. Transition probabilities, adverse events, and hospitalization rates were informed by TRISCEND II. Long-term survival outcomes were extrapolated by TR severity using published data. Utilities were estimated from the NYHA class distribution. Costs and health outcomes were discounted at 2.5% annually.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evoque\u2122 was associated with an incremental 1.76 life-years gained (LYG) and 1.63 quality-adjusted LYG (QALY). Incremental costs were \u20ac39 382 driven by device acquisition and procedure costs, resulting in an incremental cost-effectiveness ratio (ICERs) of \u20ac22 327\/LYG and \u20ac24 109\/QALY gained. Assuming no mortality difference in extrapolations, the ICER would increase to \u20ac86 428\/QALY (+258%). The model was highly sensitive to assumptions on time horizon, utility, discount rate, and post-trial mortality extrapolation, leading to major uncertainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Evoque\u2122 may represent a cost-effective strategy in severe TR patients; however, this should be interpreted with caution, as results rely heavily on extrapolated data and are subject to high structural and parameter uncertainty. The projected long-term benefits are largely model driven rather than empirically demonstrated, emphasizing the need for extended follow-up data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag137","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:37:58Z","timestamp":1778585878000},"source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of TTVR with EVOQUE system in patients with severe tricuspid regurgitation based on TRISCEND II trial"],"prefix":"10.1093","volume":"13","author":[{"given":"Apolline","family":"Grangeon","sequence":"first","affiliation":[{"name":"University Claude Bernard ISPB, Vyoo Agency , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Connock","sequence":"additional","affiliation":[{"name":"University of Birmingham, Centre for Evidence and Implementation Science (CEIS), Health Services Management Centre School of Social Policy and Society, College of Social Sciences , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-3218","authenticated-orcid":false,"given":"Peter","family":"Auguste","sequence":"additional","affiliation":[{"name":"University of Birmingham, Centre for Evidence and Implementation Science (CEIS), Health Services Management Centre School of Social Policy and Society, College of Social Sciences , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Fran\u00e7ois","family":"Obadia","sequence":"additional","affiliation":[{"name":"Hopital Cardiovasculaire Louis Pradel, Chirurgie Cardio-Vasculaire et Transplantation Cardiaque, Hospices Civils de Lyon and Claude Bernard University , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Enriquez-Sarano","sequence":"additional","affiliation":[{"name":"Abbott Northwestern Hospital , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-5529","authenticated-orcid":false,"given":"Benjamin","family":"Essayagh","sequence":"additional","affiliation":[{"name":"Department of Echocardiography, Cardio X Clinic , Cannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6723","authenticated-orcid":false,"given":"Xavier","family":"Armoiry","sequence":"additional","affiliation":[{"name":"Pharmacy Department and Laboratoire MATEIS UMR CNRS 5510, Hospices Civils de Lyon and Claude Bernard University , 8 avenue Rockefeller, Lyon 69008 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026103006214206000_xvag137-B1","author":"Mayo Clinic [Internet]"},{"key":"2026103006214206000_xvag137-B2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ehjci\/jeaa205","article-title":"New insights of tricuspid regurgitation: a large-scale prospective cohort study","volume":"22","author":"Vieitez","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026103006214206000_xvag137-B3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/ejechocard\/jeq031","article-title":"European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease)","volume":"11","author":"Lancellotti","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"2026103006214206000_xvag137-B4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jcmg.2018.06.014","article-title":"Burden of tricuspid regurgitation in patients diagnosed in the community setting","volume":"12","author":"Topilsky","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026103006214206000_xvag137-B5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa2401918","article-title":"Transcatheter valve replacement in severe tricuspid regurgitation","volume":"392","author":"Hahn","year":"2025","journal-title":"N Engl J Med"},{"key":"2026103006214206000_xvag137-B6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","article-title":"Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance","volume":"30","author":"Zoghbi","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"2026103006214206000_xvag137-B7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2026103006214206000_xvag137-B8","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026103006214206000_xvag137-B9","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1093\/eurheartj\/ehaa643","article-title":"Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes","volume":"41","author":"Dreyfus","year":"2020","journal-title":"Eur Heart J"},{"key":"2026103006214206000_xvag137-B10","author":"FDA [Internet]"},{"key":"2026103006214206000_xvag137-B11","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS)"},{"key":"2026103006214206000_xvag137-B12","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/eurheartj\/ehy641","article-title":"Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis","volume":"40","author":"Wang","year":"2019","journal-title":"Eur Heart J"},{"key":"2026103006214206000_xvag137-B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpopen.2021.100063","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"3","author":"Husereau","year":"2022","journal-title":"Health Policy Open"},{"key":"2026103006214206000_xvag137-B14","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/eurheartj\/ehaa192","article-title":"Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival","volume":"41","author":"Essayagh","year":"2020","journal-title":"Eur Heart J"},{"key":"2026103006214206000_xvag137-B15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2026103006214206000_xvag137-B16","volume-title":"Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model","author":"Royston","year":"2011"},{"key":"2026103006214206000_xvag137-B17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx504.P3373","article-title":"P3373Better health-related quality of life in patients treated with sacubitril\/valsartan compared with enalapril, irrespective of NYHA class: analysis of EQ-5D in PARADIGM-HF","volume":"38","author":"Trueman","year":"2017","journal-title":"Eur Heart J"},{"key":"2026103006214206000_xvag137-B18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40273-020-00984-6","article-title":"Health state utilities of patients with heart failure: a systematic literature review","volume":"39","author":"Di Tanna","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"2026103006214206000_xvag137-B19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s10198-022-01559-2","article-title":"Population norms in France with EQ-5D-5L: health states, value indexes, and VAS","volume":"24","author":"Gautier","year":"2023","journal-title":"Eur J Health Econ"},{"key":"2026103006214206000_xvag137-B20","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D scores for the United Kingdom","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med Decis Making"},{"key":"2026103006214206000_xvag137-B21","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/j.jval.2018.09.691","article-title":"PCV146 - Systematic literature review of utility decrements associated with the non-fatal Major adverse cardiovascular events (mace)","volume":"21","author":"Jindal","year":"2018","journal-title":"Value Health"},{"key":"2026103006214206000_xvag137-B22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00134-012-2760-4","article-title":"Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective","volume":"39","author":"Laukkanen","year":"2013","journal-title":"Intensive Care Med Mars"},{"key":"2026103006214206000_xvag137-B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1524-4733.2004.71313.x","article-title":"Using clopidogrel in non-ST-segment elevation acute coronary syndrome patients: a cost-utility analysis in Spain","volume":"7","author":"Latour-P\u00e9rez","year":"2004","journal-title":"Value Health"},{"key":"2026103006214206000_xvag137-B24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/heartjnl-2013-304598","article-title":"The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK national health service perspective","volume":"100","author":"Griffiths","year":"2014","journal-title":"Heart"},{"key":"2026103006214206000_xvag137-B25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027514","article-title":"Cost-of-illness analysis of long-term health care resource use and disease burden in patients with pulmonary embolism: insights from the PREFER in VTE registry","volume":"11","author":"Farmakis","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026103006214206000_xvag137-B26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ehf2.12432","article-title":"Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France","volume":"6","author":"Bourguignon","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026103006214206000_xvag137-B27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtcvs.2018.02.092","article-title":"Comparison of transcatheter versus surgical aortic valve implantation in high-risk patients: a nationwide study in France","volume":"156","author":"Armoiry","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026103006214206000_xvag137-B28","first-page":"0045","article-title":"De la valeur d\u2019une QALY statistique (VSQ) \u00e0 la volont\u00e9 de payer (WTP): un exemple concret qui pourrait s\u2019appliquer \u00e0 la France","volume":"42","author":"T\u00e9hard","year":"2024","journal-title":"Journal de Gestion et d \u00c9conomie M\u00e9dicales"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag137\/68275185\/xvag137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag137\/68275185\/xvag137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag137\/68275185\/xvag137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:21:50Z","timestamp":1793355710000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag137\/8676720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag137","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,5,13]]},"article-number":"xvag137"}}